Anti-b7-h3 monoclonal antibody and use thereof in cell therapy
AssigneesFuzhou Tcelltech Biotechnology Co., Ltd., Tcelltech Inc.
InventorsGangxiong HUANG, Liqun LUO
Life of this patent
Estimating the term…
Abstract
The present invention provides an anti-B7-H3 monoclonal antibody and use thereof in cell therapy. Specifically, the present invention provides an scFv, an antibody, and a specific CAR-T cell specifically targeting B7-H3. The present invention further provides an engineered immune cell capable of co-expressing a CAR targeting B7-H3 and a chimeric molecule or a secreted protein of PD-L1, the engineered immune cell having good tumor killing effects.
Claims15
An antibody binding B7-H3, wherein the antibody has:
- (1) a heavy chain variable region;
- and
- (2) a light chain variable region;
- the heavy chain variable region comprises the following three complementary determining regions (CDRs):
- CDR 1 as shown in SEQ ID NO:
- 3,
- CDR2 as shown in SEQ ID NO:
- 6, and
- CDR3 as shown in SEQ ID NO:
- 9;
- the light chain variable region comprises the following three complementary determining regions (CDRs):
- CDR1′ as shown in SEQ ID NO:
- 12,
- CDR2′ as shown in SEQ ID NO:
- 15, and
- CDR3′ as shown in SEQ ID NO:
- 18.
A CAR construct, wherein an antigen binding region of the CAR construct is an scFv that specifically binds to B7-H3, and the scFv has a heavy chain variable region and a light chain variable region;
- the heavy chain variable region comprises the following three complementary determining regions (CDRs):
- CDR1 as shown in SEQ ID NO:
- 3,
- CDR2 as shown in SEQ ID NO:
- 6, and
- CDR3 as shown in SEQ ID NO:
- 9;
- the light chain variable region comprises the following three complementary determining regions (CDRs):
- CDR1′ as shown in SEQ ID NO:
- 12,
- CDR2′ as shown in SEQ ID NO:
- 15, and
- CDR3′ as shown in SEQ ID NO:
- 18.
Dependencies are inferred from the claim text.